Intravenous infusion of DMT

ApprovedSmall molecule

UUniversity Hospital, Basel, Switzerland

Intravenous infusion of DMT is one of 41 small molecule programs targeting Mortality. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MortalityActive, not recruiting

MortalityApproved

Active, not recruiting

Competition

Competitive Landscape

108 competitors in Mortality

#DrugCompanyPhaseTrials

Crestor

AstraZeneca

Phase 3

1 2

Mounjaro

Eli Lilly

Phase 3

1 3

Winrevair

Merck & Co.

Phase 3

1 4

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

2 5

Prometrium

Ferring

Phase 3

1 6

Nydrazid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 7

Peridex

MMedline Industries

Phase 3

1 8

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 9

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 10

Isentress

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Mortality1 trial

TEAM-Project: Trial on the Effect of Anesthetics on Morbidity and Mortality

Completed·UUniversity Hospital, Basel, Switzerland·Phase 4·NCT00286585·385 enrolled

Experimental1 trial

Acute Analgesic Effects of DMT on Experimentally Induced Pain in Healthy Participants

Recruiting·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT06180759·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Intravenous infusion of DMT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intravenous infusion of DMT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intravenous infusion of DMT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Basel, Switzerland company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity Hospital, Basel, Switzerland

Intravenous infusion of DMT

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Mortality1 trial

Experimental1 trial

References

Drug Info

Quick Facts

Related News